Background. People living with human immunodeficiency virus (PLWH) are characterized by excess risk of cardiovascular diseases (CVD) and CVD risk factors compared to uninfected individuals. We investigated the association between HIV infection and abdominal obesity, elevated low-density lipoprotein cholesterol (LDL-C), hypertriglyceridemia, and hypertension in a large cohort of predominantly well-treated PLWH and matched controls.
With the introduction of combination antiretroviral therapy (cART), people living with human immunodeficiency virus (PLWH) have experienced a dramatic improvement in life expectancy [1] . Nonetheless, the observed median survival time from age 50 years is still lower in PLWH than in uninfected individuals [2] . This is partly explained by an increased risk of cardiovascular diseases (CVD) [3] , the biggest contributor to non-AIDS mortality in PLWH [4] , as well as by diseases or traits that constitute the metabolic syndrome (eg, abdominal obesity, dyslipidemia, hypertension, and diabetes) [3, [5] [6] [7] .
The redistribution of body fat from the periphery toward the abdomen (fat redistribution syndrome) is a well-known feature of HIV infection, first defined in 1998 [8] and traditionally described as an important complication of old-generation antiretroviral treatment [8] . Abdominal obesity has been linked to higher risk of CVD and CVD risk factors in PLWH [9] . Due to new-generation cART with fewer metabolic complications, the incidence of fat redistribution syndrome has declined [10] . However, the exact mechanisms behind this condition are still unclear. In addition to cART [11] , both host- [11] and viral-associated factors [12] may be involved. Whether fat redistribution syndrome is still involved in the excess risk of CVD in PLWH after the introduction of new antiretroviral regimens is yet to be determined.
We tested the hypothesis that PLWH had a higher prevalence of abdominal obesity, elevated low-density lipoprotein cholesterol (LDL-C), hypertriglyceridemia, and hypertension and that HIV infection was independently associated with these outcomes. For this purpose, we investigated the prevalence of abdominal obesity, elevated LDL-C, hypertriglyceridemia, and hypertension in a large cohort of PLWH (n = 1099) compared to matched uninfected individuals (n = 12 161); assessed whether HIV infection was independently associated with the risk of abdominal obesity, elevated LDL-C, hypertriglyceridemia, and hypertension; and aimed to identify HIV-associated predictors of these outcomes.
METHODS

Study Population
The Copenhagen Co-morbidity in HIV Infection (COCOMO) Study is a longitudinal cohort study with the aim of assessing the burden of non-AIDS comorbidities in PLWH. Inclusion criteria were a positive HIV test and age ≥18 years. Between March 2015 and December 2016, 1099 participants were enrolled in the study, representing more than 40% of the PLWH population residing in the Copenhagen area. The procedures for recruitment and data collection have been described elsewhere [13] .
A total of 12 161 uninfected individuals were recruited from the Copenhagen General Population Study (CGPS), which is an ongoing population study initiated in 2003 that includes more than 100 000 individuals who reside in the greater Copenhagen area [14] [15] [16] [17] . Of all the residents, 25% of those aged 20-40 years and 100% of those aged >40 years are invited to participate (response rate approximately 45%). Ethical approval was obtained by the Regional Ethics Committee of Copenhagen (COCOMO, H-15017350; CGPS, H-KF-01-144/01). Written informed consent was obtained from all participants.
Uninfected controls were frequency matched with PLWH by gender and 5 age year strata, and 14 randomly selected controls were identified for every woman and most men with HIV. For men aged 25-50 years, it was only possible to identify 3 to 11 controls in each 5-year age interval due to differences in the ageand sex-distribution between the HIV and control populations (Supplementary Figure 2) .
Clinical Assessments
Information about participants' demographics, physical activity, education level, smoking history, and medication use were collected using an identically structured questionnaire for COCOMO and CGPS participants. Data regarding HIV infection were obtained from review of medical charts of COCOMO participants [13] .
Trained clinic staff performed all examinations using identical protocols in both groups. Waist and hip measurements and body mass index (BMI) calculations were performed according to World Health Organization (WHO) guidelines [18] . Using an automatic digital blood pressure (BP) monitor [19] , BP was measured on the left arm after 5 minutes rest with the participant in the sitting position. Nonfasting venous blood was collected and analyzed for LDL-C, triglycerides, total cholesterol, HbA1c, and glucose. Blood samples from both COCOMO and CGPS participants were analyzed at Herlev Hospital, Copenhagen [13] .
Outcome Definitions
According to WHO guidelines, abdominal obesity was defined as waist-to-hip ratio ≥0.90 for men and ≥0.85 for women [18] .
According to American College of Cardiology-American Heart Association guidelines, elevated LDL-C was defined as LDL ≥4.14 mmol/L and/or lipid-lowering therapy [20] . As sensitivity analysis, a cutoff of LDL ≥3.00 mmol/L according to European guidelines was used [21] . According to Joint National Committee guidelines, hypertension was defined as antihypertensive treatment and/or having ≥40 mm Hg systolic and/ or ≥90 mm Hg diastolic BP values [22] . Hypertriglyceridemia was defined as triglycerides ≥2 mmol/L and/or lipid-lowering therapy [21] . Metabolic syndrome was defined using a slightly modified version of the harmonized metabolic syndrome definition [17, 23] . These criteria are depicted in Table 1 .
Statistical Analyses
Continuous variables were reported as median (interquartile range), and categorical variables were reported as percentage and frequency. Different groups were compared with t test or Mann Whitney U test for continuous data that had normal or nonnormal distribution, respectively, and χ 2 and Fisher tests for categorical data. Multivariable logistic models were fit to test associations between HIV infection and the outcomes of interest. Unadjusted and adjusted odds ratios (OR and aOR) and 95% confidence intervals were computed. Covariates included in the model were age, gender, smoking history (current, former, never smoker), origin (Scandinavian, other European Union, Middle-East and Indian subcontinent, other), educational level (none, short, vocational, middle length, university), physical activity (inactive, moderately inactive, moderately active, very active), BMI, and abdominal obesity.
Separate models for PLWH were fit to assess associations between HIV-related variables and each outcome. The following 2 models were considered: in model 1, abdominal obesity was used as an dependent variable. Independent variables included in model 1 were age, gender, smoking history, physical activity, origin, education, BMI, current CD4, CD4 nadir <200, current viral load <40 copies, time since HIV infection and cART initiation, and hepatitis C coinfection. Model 2 was used when testing elevated LDL-C, hypertriglyceridemia, and hypertension as dependent variables. Independent variables included in the model were model 1 + abdominal obesity.
As sensitivity analyses, the associations between HIV infection and abdominal obesity and elevated LDL-C, respectively, were explored in multivariable logistic regression models stratified both by present/previous didanosine (ddI)/stavudine (d4T)/zidovudine (AZT) exposure (yes vs no) and cART initiation date (before and after 2005), separately. This arbitrary and a priori-defined cutoff aims to represent the time point for the shift to newer antiretroviral regimens characterized by fewer metabolic side effects. As an additional sensitivity analysis, when testing the association between HIV infection and hypertension, logistic regression analyses were performed using all COCOMO participants and 3 randomly selected CGPS participants for every PLWH, matched using gender and 5-year age strata, thus eliminating sex and age differences between the 2 groups (Supplementary Table 1) . As an exploratory analysis, the association between HIV infection and the presence of metabolic syndrome was analyzed. Finally, in order to evaluate the possible impact of a lower threshold when defining elevated LDL-C, the association between HIV infection and elevated LDL-C was also tested using ≥3.00 mmol/L as the cutoff [21] . In all sensitivity analyses, the same covariates as in the primary analyses were included in the models. Interaction between age and HIV status was tested in multivariable logistic analysis models, with abdominal obesity, elevated LDL-C, hypertriglyceridemia, and hypertension as dependent variables. In these analyses, age was grouped into quartiles. A P value < .05 was considered statistically significant. Analyses were conducted using R (V.3.3.0).
RESULTS
Demographics
A total of 1099 COCOMO and 12 161 CGPS participants were included. Characteristics of the participants are shown in Table 1 . HIV-specific characteristics of COCOMO participants are shown in Figure 1) . Comparable results were obtained when PLWH were stratified according to ddI/d4T/AZT exposure (Supplementary Table 2 ).
The association between abdominal obesity and HIV increased as persons aged (P < .0001, test for interaction), from an aOR of 1.46 (1.06-2.00) in those aged 20-45 years to 2.75 (1.75-4.73) in those aged 60-89 years. A plot representing this interaction is shown in Figure 1 .
Abdominal obesity was associated with elevated LDL-C, hypertriglyceridemia, and hypertension in uni-and multivariable logistic regression analyses (Table 3) .
Elevated LDL-C, Hypertriglyceridemia, and Hypertension in PLWH and Uninfected Controls
PLWH had lower LDL-C but higher prevalence of current lipid-lowering treatment compared to uninfected controls (Table 1) . No difference was found in prevalence of elevated LDL-C (24.0% vs 22.7%, P value .358; Table 1 ). HIV infection was associated with elevated LDL-C in multivariable analysis (aOR, 1.32 [1.09-1.59]) only after adjusting for BMI (Table 3) . PLWH had lower systolic blood pressure and lower diastolic blood pressure compared to uninfected controls, and no difference in prevalence of current antihypertensive treatment was Table 3 ). These results were reproduced in sensitivity analyses using 3 age-and gender-matched uninfected controls for every COCOMO participant in order to achieve a perfect sex and age matching (aOR, 0.70 [0.57-0.87]).
PLWH had a higher concentration of triglycerides and a higher prevalence of hypertriglyceridemia compared to uninfected controls (Table1 
Figure 1. Predicted probability of abdominal obesity according to age in normoweight uninfected controls and people living with human immunodeficiency virus (PLWH).
Predicted probabilities for the presence of abdominal obesity in normoweight PLWH and controls were calculated using a logistic regression model that included an interaction term between human immunodeficiency virus (HIV) infection and age, age, body mass index = 22, sex = "male," origin = "Scandinavian," smoking status = "former smoker," physical activity = "moderately active," and education level = "vocational." Abbreviation: HIV, human immunodeficiency virus.
In exploratory analysis, HIV infection was associated with increased risk of metabolic syndrome (OR, 1.68 [1.39-2.03] ). 
HIV-Related Predictors of Abdominal
DISCUSSION
The redistribution of body fat toward the abdomen is associated with increased risk of CVD in PLWH [24] and was classically described as a serious, yet obsolete complication of HIV infection due to its association with old-generation cART [10] . In this study, we found that abdominal obesity remains a distinct HIV-related phenotype, in particular, among older PLWH. Furthermore, abdominal obesity was associated with elevated LDL-C, hypertriglyceridemia, and hypertension. Our results suggest a link between HIV and proaterogenic metabolic factors, partly mediated by abdominal obesity.
CVD is the leading contributor to non-AIDS morbidity and mortality in PLWH [4] . The mechanisms behind the increased risk of CVD in PLWH, however, have not been fully elucidated. The fat redistribution syndrome that characterized the early stages of HIV epidemic [8] was a serious complication of old-generation antiretroviral treatments due to its association with CVD risk factors [24] . After the introduction of cART with minor metabolic side effects, the incidence of fat redistribution syndrome among PLWH declined [10, 25] and so has the attention toward this condition. In this study, however, PLWH had higher prevalence of abdominal obesity compared to uninfected controls, despite having lower BMI. Furthermore, HIV infection was associated with increased risk of abdominal obesity, also after stratifying PLWH according to cART initiation date (pre-and post-2005). These results suggest that either HIV per se or modern cART may contribute to fat redistribution syndrome as this remains a problem even in contemporary treated PLWH. However, higher risk of abdominal obesity observed in PLWH with initiation of cART prior to 2005 supports a more harmful effect of old-generation cART on abdominal fat distribution compared to newer regimens.
Interestingly, for a given BMI, the association between HIV infection and abdominal obesity was exacerbated by age. Aging is known to cause fat tissue redistribution from subcutaneous to intraabdominal compartments [26] . This is mainly due to systemic inflammation and dysdifferentiation of preadipocytes into a proinflammatory, senescent-like and tissue-remodeling Figure 2 . Human immunodeficiency virus (HIV)-specific predictors for abdominal obesity, elevated low-density lipoprotein cholesterol (LDL-C), and hypertension. Adjusted odds ratios from multivariable logistic regression analyses with abdominal obesity, elevated LDL-C, and hypertension as dependent variables, respectively. All the models were adjusted for age, gender, smoking history, physical activity, origin, education, abdominal obesity (except when using abdominal obesity as dependent variable), body mass index, current CD4, CD4 nadir, current viral load, time since HIV infection, time since combination antiretroviral therapy initiation, and hepatitis C virus coinfection. Abbreviations: aOR, adjusted odds ratio; cART, combined antiretroviral therapy; CI, confidence interval; HCV, hepatitis C virus; VL, viral load. state, which leads to an imbalance between lipolysis and lipogenesis [27] . A similar cascade of events is described in HIVassociated fat redistribution syndrome [28] , where both host and HIV-specific factors are involved [12, 28] . In accordance with previous literature [29] , we described associations between low CD4 nadir, duration of HIV infection, and the presence of abdominal obesity. Low CD4 nadir may be considered an indirect measure of the length of ongoing viral replication [30] . A prolonged exposure to viral proteins may interfere directly with lipogenesis by inhibiting PPAR-gamma receptor activity in adipocytes [12] . We hypothesize that age-and HIV-associated fat redistribution syndromes are characterized by parallel yet interconnected pathways that amplify each other, leading to a synergistic interaction between aging and HIV infection causing abdominal obesity in PLWH. This interaction, together with the association found between abdominal obesity and elevated LDL-C, hypertriglyceridemia, and hypertension, may partly explain the increased risk of premature CVD in PLWH [31] .
Dyslipidemia has been described to be associated with increased risk of CVD in PLWH [3] . Consistent with previous literature [3] , we found that HIV infection was associated with higher risk of hypertriglyceridemia and, after adjusting for BMI, elevated LDL-C. However, when only PLWH who initiate treatment after 2005 were considered, no evidence of association between HIV infection and elevated LDL-C was found. Although power for this analysis was lower than in primary analyses, this result may be due to the exposure to different antiretroviral regimes introduced prior to and after 2005, the latter being characterized by fewer metabolic side effects compared to older-generation cART. While having declined in the last decade [25] , the prevalence of lipid metabolism disturbances and abdominal obesity still remains high in PLWH and warrants continued attention.
Hypertension is a major CVD risk factor [32] , and the possible association between HIV infection and hypertension has been widely studied, with contradictory results [5, [33] [34] [35] [36] [37] [38] . PLWH have been described to have lower [33, 34] , comparable [35, 36] , and higher [5, 37, 38] prevalence of hypertension compared to uninfected controls. In contrast to our predefined hypothesis, we found that PLWH had lower prevalence of hypertension and that HIV infection was associated with lower risk of hypertension, even in the sensitivity analysis performed. Of note, the prevalence of hypertension in CGPS participants was high (57.9%), as described in previous studies [14, 19] , yet comparable to other Danish general population studies [39] . Due to the size of cohorts included in this study and the overlapping recruitment area between the 2 groups, we do not believe that sample size or geographical differences explain the findings. There is no obvious biological mechanism that could explain why HIV infection should protect against hypertension, and we suggest that the association found between HIV infection and low risk of hypertension may be due to confounding factors we were not able to account for. It is worth noticing that this finding was mainly driven by undiagnosed and thus untreated hypertension, which may represent a more pronounced white-coat effect in the uninfected population, which is less exposed to the hospital environment compared to PLWH.
HIV was associated with increased odds of abdominal obesity, which was associated with elevated LDL, hypertriglyceridemia, and hypertension. In turn, HIV was associated with increased odds for both elevated LDL and hypertriglyceridemia. As discussed above, PLWH had lower odds of hypertension. In contrast with the direct and detrimental impact that HIV per se and cART have been described to have on both fat tissue and lipid metabolism [28] , the effect of HIV on hypertension may be predominantly indirect, mediated by several factors including abdominal obesity, which may result in weaker associations.
The main limitation to the present study is that PLWH and uninfected controls were included from 2 centers, University of Copenhagen-Rigshospitalet and University of Copenhagen-Herlev Hospital, respectively. The use of different equipment at the 2 sites may have led to minor methodologic differences that we were not able to account for. However, the same model of equipment was used in both centers, and all the investigations were performed by trained medical staff following identical protocols. Minor differences in age and gender found between the 2 populations may explain part of the differences in the prevalence of the outcomes. However, a possible confounding effect of these variables was reduced by adjusting for, among the others, age and gender in multivariable analyses.
To our knowledge, this is the largest study to report data regarding abdominal obesity, elevated LDL-C, hypertriglyceridemia, and hypertension in PLWH and uninfected controls. Adjusting for lifestyle and demographic factors, we were able to investigate the effect of HIV infection and to reduce the effect of possible confounders.
In conclusion, our study suggests that abnormal fat distribution and abdominal obesity remain prominent features of contemporarily treated PLWH and may contribute to continued excess risk of premature CVD in this population, given both the deleterious interaction found between HIV infection and aging in causing abdominal obesity and its association with elevated LDL-C, hypertriglyceridemia, and hypertension. Renewed attention by the medical community toward the abdominal obesity phenotype and innovative interventions that target this condition are therefore needed in order to reduce the risk of CVD in PLWH.
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